Huminsulin Profil Iii Lilly Deutschland Gmbh (Insulin Human (Rdna))

Huminsulin Profil III is prescribed to improve glycemic control in patients with diabetes mellitus.

• Adults with type 1 diabetes mellitus requiring insulin therapy.
• Adults with type 2 diabetes mellitus when oral agents are insufficient.
• Mealtime (prandial) insulin to control post‑prandial glucose spikes.
• Hospitalized patients needing rapid glucose management.
• Pediatric patients with type 1 diabetes under specialist supervision.
• Patients undergoing surgery who need tight peri‑operative glucose control.
• Individuals using insulin pump therapy as a rapid‑acting component.

• Huminsulin Profil III contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface, increasing glucose uptake, and suppressing hepatic gluconeogenesis. This interaction lowers blood glucose concentrations and helps maintain metabolic homeostasis.

Huminsulin Profil III can cause adverse reactions ranging from mild, self‑limited events to rare but serious conditions related to its glucose‑lowering effect or injection vehicle.

Common

• Mild hypoglycemia (blood glucose <70 mg/dL) with shakiness or sweating.
• Redness, swelling, itching or bruising at the injection site, usually resolving quickly.
• Small lumps of fatty tissue (lipohypertrophy) under the skin from repeated injections, which may affect absorption.
• Transient weight gain or fluid retention during the initial weeks of therapy.
• Temporary nausea or abdominal discomfort after injection.

Serious

• Severe hypoglycemia with confusion, seizures, or loss of consciousness.
• Anaphylactic reaction (urticaria, bronchospasm, hypotension) requiring immediate care.
• Significant edema or worsening heart failure, especially in patients with cardiac disease.
• Hypokalemia that may cause cardiac arrhythmias, particularly with diuretic use.
• Development of insulin antibodies that can alter insulin action or cause allergic signs.

Precautions for Huminsulin Profil III focus on patient assessment, monitoring, and conditions that may affect insulin requirements or safety.

• Assess renal or hepatic impairment as they may alter insulin clearance.
• Adjust dose during illness, infection, or stress.
• Monitor blood glucose frequently to avoid hypoglycemia.
• Use caution in pregnant or breastfeeding women; consult healthcare provider.
• Avoid use in patients with known hypersensitivity to human insulin or excipients.
• Consider cardiovascular status; edema may worsen heart failure.

Huminsulin Profil III may interact with other medicines that influence blood glucose levels or insulin pharmacodynamics.

Avoid

• Simultaneous administration of other rapid‑acting insulins without dose reduction.
• High‑dose beta‑blockers that can conceal hypoglycemia warning signs.
• Concurrent use of GLP‑1 receptor agonists may increase risk of gastrointestinal side effects and affect glucose control.

Use with caution

• Oral antidiabetic agents (sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Corticosteroids, thiazide diuretics, or sympathomimetics that raise glucose and may require higher insulin doses.
• Alcohol consumption, especially binge drinking, which can cause delayed hypoglycemia.
• Pregnancy and lactation, requiring close monitoring and possible dose adjustments.